MIGDAL HAEMEK, Israel, and SAN JOSE, California — TowerJazz and Axbio Inc. announced the release of a microfluidics Bio-CMOS device for molecular in vitro diagnostic (IVD), based on TowerJazz’s 65nm RFCMOS platform, following a successful development in its 300mm manufacturing facility in Uozu, Japan. This unique device, planned to be in production by mid-2019, combined with highly innovative automation features and disposable cartridge, offers a frontier solution for the medical market.
This technological breakthrough device enables tests to be handled on premises, in the clinical lab itself, with no need to send blood samples out for results. In addition, minimal blood draw is required for complete diagnostics making it highly efficient, facilitating time and cost savings, while enabling extremely accurate and thorough results in a very short period of time with minimal effort.
Axbio’s microfluidic-CMOS platform device and systems are expected to provide leading-edge technologies in many health-related applications, such as molecular diagnostics, drug discovery, liquid biopsy, microbiology, agriculture, and environmental science.
TowerJazz’s 65nm RFCMOS platform supports a wide range of CMOS and RF applications with state-of-the-art RF modeling for MOSFETs, inductors and transmission lines, a very large set of metal combination and a full set of RFCMOS elements. RF applications such as WiFi 802.11, Wireless HDMI, and WiGi, that require 65nm mmWave technology, can now utilize modeling capabilities up to 110GHz. The Company’s customized process solutions, together with its optimized layout, is answering the extremely unique technological demands of the IVD market by allowing ultra-high density (UHD) of sensing array along with extremely high-resolution capabilities. In addition, this platform is automotive qualified.
For more information, please visit: www.axbio.co.